Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs - supplementary material

<strong>Supplementary Table 1: Tumor-Specific Trial Search Strategy</strong> <strong>Supplementary Table 2: Tumor-Agnostic Trial Search Strategy</strong> <strong>Exhibit 3: Tumor-agnostic trial characteristics</strong> <strong>Supplementary Table 4: Tumor-agnostic cohort characteristics</strong> <strong>Supplementary Table 5: Progression-free survival (PFS) and overall survival (OS) estimates from tumor-agnostic trials.</strong> <strong>Supplementary Table 6: Tumor-specific trial characteristics</strong> <strong>Supplementary Table 7: Tumor-specific cohort characteristics</strong> <strong>Supplementary Table 8. Progression-free survival (PFS) and overall survival (OS) estimates from tumor-specific trials. </strong> <strong>Supplementary Figure 1: Meta-analysis of BRAF inhibitors by trial type.</strong> <strong>Supplementary Figure 2: Meta-analysis of BRAF/MEK inhibitors by trial type.</strong> <br>